Camp4 Therapeutics (CAMP) Total Non-Current Liabilities (2023 - 2026)
Camp4 Therapeutics recorded quarterly Total Non-Current Liabilities of $23.6 million in Q1 2026, down 6.85% quarter-over-quarter from $25.3 million in Q4 2025, and up 110.8% year-over-year from $11.2 million in Q1 2025.
Camp4 Therapeutics' Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $23.6 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 110.8% year-over-year to $23.6 million; the TTM figure through Mar 2026 stood at $23.6 million (up 110.8% YoY), while the FY2025 annual figure was $25.3 million, up 67.14% from the prior year.
- Total Non-Current Liabilities came in at $23.6 million for Q1 2026 at Camp4 Therapeutics, down from $25.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $25.3 million in Q4 2025 to a low of $11.0 million in Q3 2025.
- A 4-year average of $16.5 million and a median of $15.8 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities sank 39.55% in 2025 and jumped 110.8% in 2026, its largest moves.
- Camp4 Therapeutics' Total Non-Current Liabilities stood at $16.5 million in 2023, then declined by 8.25% to $15.2 million in 2024, then soared by 67.14% to $25.3 million in 2025, then slipped by 6.85% to $23.6 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $23.6 million, $25.3 million, and $11.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Camp4 Therapeutics | 245.89 Mn | 245.89 Mn | - | 23.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.61 Mn |
| Dec 31, 2025 | 25.34 Mn |
| Sep 30, 2025 | 11.00 Mn |
| Jun 30, 2025 | 11.29 Mn |
| Mar 31, 2025 | 11.20 Mn |
| Dec 31, 2024 | 15.16 Mn |
| Sep 30, 2024 | 18.19 Mn |
| Dec 31, 2023 | 16.53 Mn |